JP2021534138A5 - - Google Patents

Info

Publication number
JP2021534138A5
JP2021534138A5 JP2021507456A JP2021507456A JP2021534138A5 JP 2021534138 A5 JP2021534138 A5 JP 2021534138A5 JP 2021507456 A JP2021507456 A JP 2021507456A JP 2021507456 A JP2021507456 A JP 2021507456A JP 2021534138 A5 JP2021534138 A5 JP 2021534138A5
Authority
JP
Japan
Prior art keywords
xrpd
peaks
omecamutib
cukα irradiation
pattern
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021507456A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021534138A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/046726 external-priority patent/WO2020037164A1/en
Publication of JP2021534138A publication Critical patent/JP2021534138A/ja
Publication of JP2021534138A5 publication Critical patent/JP2021534138A5/ja
Priority to JP2024090471A priority Critical patent/JP2024123028A/ja
Priority to JP2025066074A priority patent/JP2025108571A/ja
Pending legal-status Critical Current

Links

JP2021507456A 2018-08-17 2019-08-16 オメカムチブメカルビルの塩及び結晶形態 Pending JP2021534138A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2024090471A JP2024123028A (ja) 2018-08-17 2024-06-04 オメカムチブメカルビルの塩及び結晶形態
JP2025066074A JP2025108571A (ja) 2018-08-17 2025-04-14 オメカムチブメカルビルの塩及び結晶形態

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862765090P 2018-08-17 2018-08-17
US62/765,090 2018-08-17
PCT/US2019/046726 WO2020037164A1 (en) 2018-08-17 2019-08-16 Salts and crystal forms of omecamtiv mecarbil

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024090471A Division JP2024123028A (ja) 2018-08-17 2024-06-04 オメカムチブメカルビルの塩及び結晶形態

Publications (2)

Publication Number Publication Date
JP2021534138A JP2021534138A (ja) 2021-12-09
JP2021534138A5 true JP2021534138A5 (cg-RX-API-DMAC7.html) 2022-08-22

Family

ID=67809688

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2021507456A Pending JP2021534138A (ja) 2018-08-17 2019-08-16 オメカムチブメカルビルの塩及び結晶形態
JP2024090471A Withdrawn JP2024123028A (ja) 2018-08-17 2024-06-04 オメカムチブメカルビルの塩及び結晶形態
JP2025066074A Pending JP2025108571A (ja) 2018-08-17 2025-04-14 オメカムチブメカルビルの塩及び結晶形態

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2024090471A Withdrawn JP2024123028A (ja) 2018-08-17 2024-06-04 オメカムチブメカルビルの塩及び結晶形態
JP2025066074A Pending JP2025108571A (ja) 2018-08-17 2025-04-14 オメカムチブメカルビルの塩及び結晶形態

Country Status (8)

Country Link
US (3) US11465969B2 (cg-RX-API-DMAC7.html)
EP (1) EP3837009A1 (cg-RX-API-DMAC7.html)
JP (3) JP2021534138A (cg-RX-API-DMAC7.html)
AU (2) AU2019321573B2 (cg-RX-API-DMAC7.html)
CA (1) CA3108800A1 (cg-RX-API-DMAC7.html)
MA (1) MA53226A (cg-RX-API-DMAC7.html)
MX (2) MX2021001792A (cg-RX-API-DMAC7.html)
WO (1) WO2020037164A1 (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7507735B2 (en) 2004-06-17 2009-03-24 Cytokinetics, Inc. Compounds, compositions and methods
EP3821882A1 (en) 2013-03-14 2021-05-19 Amgen Inc. Heterocyclic compounds and their uses
JP2020526483A (ja) 2017-06-30 2020-08-31 アムジエン・インコーポレーテツド 心筋節活性化剤で心不全を治療する方法
MX2021009594A (es) 2017-06-30 2022-10-24 Amgen Inc Sintesis de omecamtiv mecarbil.
BR112020004800A2 (pt) 2017-09-13 2020-09-24 Amgen Inc. compostos de bisamida ativantes do sarcômero e seus usos
DK3594199T3 (da) 2018-07-09 2020-09-14 Fis Fabbrica Italiana Sintetici Spa Krystallinsk 2-flour-3-nitrotoluen og proces til forberedelse deraf
EP3837009A1 (en) * 2018-08-17 2021-06-23 Amgen, Inc Salts and crystal forms of omecamtiv mecarbil
US12442027B2 (en) 2018-12-18 2025-10-14 Amgen Inc. Method of reducing aromatic nitro compounds
US20220340542A1 (en) * 2019-09-19 2022-10-27 Synthon B.V. Salts of omecamtiv mecarbil and solid forms thereof
US20220348543A1 (en) * 2019-09-19 2022-11-03 Synthon B.V. Salts of omecamtiv mecarbil and solid forms thereof
WO2021070123A1 (en) * 2019-10-09 2021-04-15 Dr. Reddy’S Laboratories Limited Solid forms of omecamtiv mecarbil dihydrochloride and processes thereof
IL302850A (en) 2020-11-12 2023-07-01 Amgen Inc Methods of treating heart failure by administering OMECAMTIV MECARBIL
WO2022177927A1 (en) 2021-02-16 2022-08-25 Assia Chemical Industries Ltd Unhydrous crystalline form of omecamtiv mecarbil dihydrobromide salt
AU2022232919A1 (en) 2021-03-10 2023-10-19 Amgen Inc. Synthesis of omecamtiv mecarbil
US11986474B1 (en) 2023-06-27 2024-05-21 Cytokinetics, Incorporated Methods for treating heart failure by administering cardiac sarcomere activators

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US7507735B2 (en) 2004-06-17 2009-03-24 Cytokinetics, Inc. Compounds, compositions and methods
TW200808321A (en) 2005-12-15 2008-02-16 Cytokinetics Inc Certain chemical entities, compositions and methods
US20090192168A1 (en) * 2008-01-04 2009-07-30 Alex Muci Compounds, Compositions and Methods
EP3821882A1 (en) 2013-03-14 2021-05-19 Amgen Inc. Heterocyclic compounds and their uses
JP6634368B2 (ja) 2013-03-14 2020-01-22 アムジエン・インコーポレーテツド 複素環式化合物及びそれらの使用
EP3250557B1 (en) 2015-01-29 2024-11-20 Signal Pharmaceuticals, LLC Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
JP6858716B2 (ja) 2015-06-26 2021-04-14 アムジエン・インコーポレーテツド 心筋ミオシン活性化剤と洞房結節If電流阻害剤の併用療法
JP2020526483A (ja) 2017-06-30 2020-08-31 アムジエン・インコーポレーテツド 心筋節活性化剤で心不全を治療する方法
MX2021009594A (es) 2017-06-30 2022-10-24 Amgen Inc Sintesis de omecamtiv mecarbil.
DK3594199T3 (da) 2018-07-09 2020-09-14 Fis Fabbrica Italiana Sintetici Spa Krystallinsk 2-flour-3-nitrotoluen og proces til forberedelse deraf
WO2020014406A1 (en) 2018-07-12 2020-01-16 Assia Chemical Industries Ltd. Solid state forms of omecamtiv mecarbil & omecamtiv mecarbil dihcl
EP3837009A1 (en) * 2018-08-17 2021-06-23 Amgen, Inc Salts and crystal forms of omecamtiv mecarbil
US12442027B2 (en) 2018-12-18 2025-10-14 Amgen Inc. Method of reducing aromatic nitro compounds
US20220340542A1 (en) 2019-09-19 2022-10-27 Synthon B.V. Salts of omecamtiv mecarbil and solid forms thereof
US20220348543A1 (en) 2019-09-19 2022-11-03 Synthon B.V. Salts of omecamtiv mecarbil and solid forms thereof
WO2021070123A1 (en) 2019-10-09 2021-04-15 Dr. Reddy’S Laboratories Limited Solid forms of omecamtiv mecarbil dihydrochloride and processes thereof
US20220411374A1 (en) 2019-10-09 2022-12-29 Dr. Reddy's Laboratories Limited Alternate processes for the preparation of omecamtiv mecarbil
CN114929671B (zh) 2020-01-03 2024-04-16 苏州科睿思制药有限公司 化合物i二盐酸盐的共晶及其制备方法和用途
WO2021163172A1 (en) 2020-02-10 2021-08-19 Amgen Inc. Omecamtiv mecarbil tablet
IL302850A (en) 2020-11-12 2023-07-01 Amgen Inc Methods of treating heart failure by administering OMECAMTIV MECARBIL
AU2022232919A1 (en) 2021-03-10 2023-10-19 Amgen Inc. Synthesis of omecamtiv mecarbil
US11986474B1 (en) 2023-06-27 2024-05-21 Cytokinetics, Incorporated Methods for treating heart failure by administering cardiac sarcomere activators

Similar Documents

Publication Publication Date Title
EP1955697B1 (en) 2-aminobenzamide derivatives as vanilloid receptor 1 (vr1) inhibitors useful for the treatment of pain or bladder function disorder
CA2150812C (en) Catechol diethers as selective pde iv inhibitors
US20120172382A1 (en) Pyridone amides and analogs exhibiting anti-cancer and anti-proliferative activities
JP2005505618A5 (cg-RX-API-DMAC7.html)
JP2007516218A (ja) イソキノリノンカリウムチャネル阻害剤
JP2010523556A5 (cg-RX-API-DMAC7.html)
ES2404506T3 (es) Sales hidroxibenzoato de compuestos de metanicotina
JP2005508967A5 (cg-RX-API-DMAC7.html)
SK6252000A3 (en) Indazole bioisostere replacement of catechol in therapeutically active compounds
CA2730078A1 (en) Nitrogen-containing aromatic heterocyclyl compound
US20150313883A1 (en) Hydroxybenzoate salts of metanicotine compounds
KR20100016593A (ko) 신규한 바닐로이드 수용체 리간드 및 약제의 제조를 위한 이의 용도
MX2014012992A (es) Derivado de quinazolindiona.
WO2011002103A2 (en) A cycloalkane derivative
NZ589019A (en) 3, 4 - substituted piperidine derivatives as renin inhibitors
WO2011148956A1 (ja) 縮合イミダゾール誘導体
AU2010271746A1 (en) 2-[[[2-[(hydroxyacetyl)amino]-4-pyridinyl]methyl]thio]-N-[4-(trifluoromethoxy) phenyl]-3-pyridinecarboxamide benzene- sulfonate, crystals of same, polymorphs thereof, and processes for production thereof
JP2005532397A5 (cg-RX-API-DMAC7.html)
JP2023530786A5 (cg-RX-API-DMAC7.html)
US8017785B2 (en) Salt forms of (2S)-(4E)-N-methyl-5-[3-(5-isopropoxypyridin)y1]-4-penten 2-amine
JP2007518798A5 (cg-RX-API-DMAC7.html)
WO2011030864A1 (ja) アニリン化合物
WO2007063821A1 (ja) 光学活性なジヒドロピリジン誘導体の酸付加塩
JP2009513580A5 (cg-RX-API-DMAC7.html)
CN107573302B (zh) 芳基哌嗪化合物及其制备方法和用途